On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of…
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
On Mar. 23, 2022, Quest Diagnostics announced that it had been granted a contract by the Centers for…
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
On Mar. 21, 2022, Moderna announced announced a new supply agreement with the Swiss Federal Government for seven…
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Mar. 17, 2022, Eiger BioPharmaceuticals announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations…
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) has launched a…
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDCï¾’s Advisory Committee on Immunization…
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
On Mar. 10, 2022, the City of Hope announced that its COVID-19 investigational vaccine licensed to GeoVax Labs…
On Mar. 9, 2022, Pfizer announced today that it has initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of…
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Mar. 4, 2022, the CDC reported that COVID-19 vaccination coverage with the first dose of the primary…
On Mar. 3, 2022, the WHO and the Medicines Patent Pool (MPP) jointly welcomed the announcement that the…
On Mar. 2, 2022, Sorrento Therapeutics announced that it had received clearance from the FDA for its investigational…
On Mar. 1, 2022, the CDC reported that Two doses of Pfizer-BioNTech vaccine protect against COVID-19ï¾–associated emergency department…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…